Literature DB >> 8781781

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

A Sparreboom1, O Van Tellingen, E J Scherrenburg, J J Boesen, M T Huizing, W J Nooijen, C Versluis, J H Beijnen.   

Abstract

We have developed a procedure suited for the isolation of metabolites of docetaxel (Taxotere) from human feces. The compounds were extracted from the feces with diethyl ether and further purified by (semipreparative) HPLC. Four metabolic products were obtained in submilligram quantities. Analytical HPLC with photodiode array detection showed that the purity of each compound was higher than 98%. There structures have been characterized by UV absorption and FAB/MS. All four compounds were oxidation products of the tert-butyl group attached to the C13-side chain, and corresponded to structures identified previously. The purified products were used for evaluating their cytotoxic activities against a human ovarian cancer (A2780) and a rat colon cancer (CC531) cell line, and their myelosuppressive effects in a hematopoietic progenitor toxicity assay. Although distinctions in biological activities between the compounds were evident, all metabolites showed a marked reduction in both cytotoxic and myelotoxic properties.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781781

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  Docetaxel: a review of its use in non-small cell lung cancer.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 2.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of docetaxel : recent developments.

Authors:  Sharyn D Baker; Alex Sparreboom; Jaap Verweij
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Authors:  Stefanie D Krens; Howard L McLeod; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

5.  Metabolism and excretion of novel pulmonary-targeting docetaxel liposome in rabbits.

Authors:  Jie Wang; Li Zhang; Lijuan Wang; Zhonghong Liu; Yu Yu
Journal:  Korean J Physiol Pharmacol       Date:  2016-12-21       Impact factor: 2.016

6.  Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model.

Authors:  Chenrui Li; Zhijun Wang; Qian Wang; Rebecca Lucinda Ka Yan Ho; Ying Huang; Moses S S Chow; Christopher Wai Kei Lam; Zhong Zuo
Journal:  Oncotarget       Date:  2017-12-14

Review 7.  Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.

Authors:  Maarten van Eijk; René J Boosman; Alfred H Schinkel; Alwin D R Huitema; Jos H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-15       Impact factor: 3.333

8.  Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity.

Authors:  A Yamada; K Maeda; K Kiyotani; T Mushiroda; Y Nakamura; Y Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-07-23

9.  ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients.

Authors:  Anand Patil; Bharati Shriyan; Parsshava Mehta; Mrudula Patil; Murari Gurjar; Manjunath Nookala; Vijay Patil; Amit Joshi; Vanita Noronha; Kumar Prabhash; Vikram Gota
Journal:  Cancer Med       Date:  2021-06-22       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.